

MEDIA ALERT • MEDIA ALERT • MEDIA ALERT

Alcon Elevates Dry Eye Care with Latest Innovation, Systane iLux² MGD Thermal Pulsation System

April 4, 2022

Alcon, the global leader in eye care dedicated to helping people see brilliantly, is excited to introduce its latest dry eye innovation, the Systane® iLux²® Meibomian Gland Dysfunction (MGD) Thermal Pulsation System. With new imaging technology to capture infrared photos and HD video of the meibomian glands, this all-in-one handheld device allows patients to see the need for treatment and visualize their procedure, and experience results in as little as one week.¹

“Alcon is dedicated to the advancement of medical device technology and providing Eye Care Professionals (ECPs) with the tools needed to effectively treat their patients,” said Fred Ellis, Vice President, U.S. Pharmaceutical and Dry Eye, Alcon. “With the Systane iLux² MGD Thermal Pulsation System, ECPs will be able to further patient trust and confidence because seeing is believing.”

Introduction of Systane iLux² MGD Thermal Pulsation System Makes the Invisible, Visible

The Systane iLux² MGD Thermal Pulsation System expands Alcon’s current dry eye treatment offerings and allows practitioners to tailor MGD treatment to the needs of each of their patients in eight to twelve minutes.^{1,2}

- The device’s imaging technology allows patients to view both their meibomian glands and treatment through infrared imaging and HD video of the procedure.
- ECPs can customize heat and compression across each easy-to-visualize treatment zone.

Systane iLux² MGD Thermal Pulsation System can help Eye Care Practitioners build a strong, trusting relationship with their patients by boosting the credibility of their treatment recommendation through direct visualization of the disease and tracking the disease over time through stored meibomian gland images.

“56% of MGD patients see four or more Eye Care Practitioners in search of proper diagnosis and relief.³This is a prevalent diagnosis in my practice, and it is essential for me to stay on top of the latest treatment options,” said Eric D. Donnenfeld, M.D., FAAO, Ophthalmic Consultants of Long Island, NY. “The new Systane iLux² MGD Thermal Pulsation System gives me the confidence to customize treatments based on my patients’ needs and help them see, understand and value their MGD treatment.”

For more information or to request upgrade information, visit SystaneiLux.com, contact your Alcon sales representative or email us at iLUX@alcon.com.

About Alcon

Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 24,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.

Trademarks are the property of their respective owners.

IMPORTANT PRODUCT INFORMATION

Indication: The *Systane® iLux²* is indicated for the application of localized heat and pressure therapy in adult patients with meibomian gland dysfunction (MGD), which is associated with evaporative dry eye, and to capture/store digital images and video of the meibomian glands.

Contraindications:

Do NOT use the *Systane® iLux²* in patients with the following conditions: patients whose pupils have been pharmaceutically dilated; patients with ocular injury or trauma, chemical burns, or limbal stem cell deficiency (within prior 3 months); patients with active ocular herpes zoster or simplex of eye or eyelid or a history of these within prior 3 months; patients with cicatricial lid margin disease; patients with active ocular infection, active ocular inflammation or history of chronic, recurrent ocular inflammation within prior 3 months; patients with an ocular surface abnormality that may compromise corneal integrity; patients with lid surface abnormalities that affect lid function in either eye; patients with aphakia; or patients with permanent makeup or tattoos on their eyelids.

Warnings/Precautions:

Federal law restricts this device to sale by or on the order of a licensed healthcare practitioner.

The Disposable may not fit all eyes, such as eyes with small palpebral fornices. Use of the *Systane® iLux²* is NOT recommended in patients with the following conditions: moderate to

severe allergic, vernal or giant papillary conjunctivitis; severe eyelid inflammation; systemic disease conditions that cause dry eye; in patients who are taking medications known to cause dryness; patients with punctal plugs, or patients who have undergone ocular surgery within prior 3 months.

Potential Adverse Reactions:

Potential adverse effects may occur because of the procedure. These effects include, but are not limited to, the onset or increase in: eyelid/eye pain requiring discontinuation of the treatment procedure, eyelid irritation or inflammation, temporary reddening of the skin, ocular surface irritation or inflammation (e.g., corneal abrasion, conjunctival edema or conjunctival injection (hyperemia)), and ocular symptoms (e.g., burning, stinging, tearing, itching, discharge, redness, foreign body sensation, visual disturbance, sensitivity to light).

Attention: Please refer to the User Manual for a complete list of contraindications, instructions for use, warnings and precautions for the *Systane® iLux²*.

References

1. Tauber J, Owen J, Bloomenstein M, Hovanesian J, Bullimore MA. Comparison of the iLux and the LipiFlow for the Treatment of Meibomian Gland Dysfunction and Symptoms: A Randomized Clinical Trial. *Clin Ophthalmol*. 2020;14:405-418.
2. Alcon data on file, 2019.
3. The Dry Eye Problem. Building Your Dry Eye Center of Excellence. *Review of Optometric Business* supplement. <https://www.reviewob.com/building-your-dry-eye-center-of-excellence/>. Accessed April 4, 2022.

Connect with us on



Media Relations

Wes Warnock
+ 41 589 112 111 (Geneva)
+ 1 817 615 2501 (Fort Worth)
globalmedia.relations@alcon.com